These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 15184261)

  • 41. BRCA1 and BRCA2 germline mutations in Korean patients with sporadic breast cancer.
    Seo JH; Cho DY; Ahn SH; Yoon KS; Kang CS; Cho HM; Lee HS; Choe JJ; Choi CW; Kim BS; Shin SW; Kim YH; Kim JS; Son GS; Lee JB; Koo BH
    Hum Mutat; 2004 Oct; 24(4):350. PubMed ID: 15365993
    [TBL] [Abstract][Full Text] [Related]  

  • 42. High risk for ovarian cancer in a prospective series is restricted to BRCA1/2 mutation carriers.
    Maehle L; Apold J; Paulsen T; Hagen B; Løvslett K; Fiane B; Van Ghelue M; Clark N; Møller P
    Clin Cancer Res; 2008 Nov; 14(22):7569-73. PubMed ID: 19010876
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype-phenotype correlations.
    Gallardo M; Silva A; Rubio L; Alvarez C; Torrealba C; Salinas M; Tapia T; Faundez P; Palma L; Riccio ME; Paredes H; Rodriguez M; Cruz A; Rousseau C; King MC; Camus M; Alvarez M; Carvallo P
    Breast Cancer Res Treat; 2006 Jan; 95(1):81-7. PubMed ID: 16261400
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mutation analysis and characterization of HSD17B2 sequence variants in breast cancer cases from French Canadian families with high risk of breast and ovarian cancer.
    Plourde M; Manhes C; Leblanc G; Durocher F; Dumont M; Sinilnikova O; ; Simard J
    J Mol Endocrinol; 2008 Apr; 40(4):161-72. PubMed ID: 18372405
    [TBL] [Abstract][Full Text] [Related]  

  • 45. BRCA1 mutations and polymorphisms in a hospital-based consecutive series of breast cancer patients from Apulia, Italy.
    Tommasi S; Crapolicchio A; Lacalamita R; Bruno M; Monaco A; Petroni S; Schittulli F; Longo S; Digennaro M; Calistri D; Mangia A; Paradiso A
    Mutat Res; 2005 Oct; 578(1-2):395-405. PubMed ID: 16026807
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The spectrum and incidence of BRCA1 pathogenic mutations in Slovak breast/ovarian cancer families.
    Konecny M; Vizvaryova M; Weismanova E; Ilencikova D; Mlkva I; Weismann P; Machackova G; Kausitz J
    Neoplasma; 2007; 54(2):137-42. PubMed ID: 17319787
    [TBL] [Abstract][Full Text] [Related]  

  • 47. BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study.
    Musolino A; Bella MA; Bortesi B; Michiara M; Naldi N; Zanelli P; Capelletti M; Pezzuolo D; Camisa R; Savi M; Neri TM; Ardizzoni A
    Breast; 2007 Jun; 16(3):280-92. PubMed ID: 17257844
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mutation screening of the BRCA1 gene in sporadic breast cancer in southern Chinese populations.
    Haitian Z; Yunfei L; Jian Z; Jian L; Qinghua L; Fuqiang W
    Breast; 2008 Dec; 17(6):563-7. PubMed ID: 18835712
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A yeast recombination assay to characterize human BRCA1 missense variants of unknown pathological significance.
    Caligo MA; Bonatti F; Guidugli L; Aretini P; Galli A
    Hum Mutat; 2009 Jan; 30(1):123-33. PubMed ID: 18680205
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients.
    Alsner J; Jensen V; Kyndi M; Offersen BV; Vu P; Børresen-Dale AL; Overgaard J
    Acta Oncol; 2008; 47(4):600-7. PubMed ID: 18465328
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Structural consequences of a cancer-causing BRCA1-BRCT missense mutation.
    Williams RS; Glover JN
    J Biol Chem; 2003 Jan; 278(4):2630-5. PubMed ID: 12427738
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Functional analysis of BRCA1 C-terminal missense mutations identified in breast and ovarian cancer families.
    Vallon-Christersson J; Cayanan C; Haraldsson K; Loman N; Bergthorsson JT; Brøndum-Nielsen K; Gerdes AM; Møller P; Kristoffersson U; Olsson H; Borg A; Monteiro AN
    Hum Mol Genet; 2001 Feb; 10(4):353-60. PubMed ID: 11157798
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Conservation of biotindase in mammals and identification of the putative biotinidase gene in Drosophila melanogaster.
    Swango KL; Wolf B
    Mol Genet Metab; 2001 Dec; 74(4):492-9. PubMed ID: 11749055
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Missense mutations in transmembrane domains of proteins: phenotypic propensity of polar residues for human disease.
    Partridge AW; Therien AG; Deber CM
    Proteins; 2004 Mar; 54(4):648-56. PubMed ID: 14997561
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Functional assay for BRCA1: mutagenesis of the COOH-terminal region reveals critical residues for transcription activation.
    Hayes F; Cayanan C; Barillà D; Monteiro AN
    Cancer Res; 2000 May; 60(9):2411-8. PubMed ID: 10811118
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Mapping of BRCT1 domain of BRCA1 with chromatin unfolding activity].
    Ye QN; Hu YF; Zhong HJ; Li R; Huang CF
    Sheng Wu Gong Cheng Xue Bao; 2002 Nov; 18(6):656-61. PubMed ID: 12674632
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Detection of protein folding defects caused by BRCA1-BRCT truncation and missense mutations.
    Williams RS; Chasman DI; Hau DD; Hui B; Lau AY; Glover JN
    J Biol Chem; 2003 Dec; 278(52):53007-16. PubMed ID: 14534301
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Structure of the BRCT repeats of BRCA1 bound to a BACH1 phosphopeptide: implications for signaling.
    Shiozaki EN; Gu L; Yan N; Shi Y
    Mol Cell; 2004 May; 14(3):405-12. PubMed ID: 15125843
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Human, canine and murine BRCA1 genes: sequence comparison among species.
    Szabo CI; Wagner LA; Francisco LV; Roach JC; Argonza R; King MC; Ostrander EA
    Hum Mol Genet; 1996 Sep; 5(9):1289-98. PubMed ID: 8872468
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impact of amino acid substitutions at secondary structures in the BRCT domains of the tumor suppressor BRCA1: Implications for clinical annotation.
    Fernandes VC; Golubeva VA; Di Pietro G; Shields C; Amankwah K; Nepomuceno TC; de Gregoriis G; Abreu RBV; Harro C; Gomes TT; Silva RF; Suarez-Kurtz G; Couch FJ; Iversen ES; Monteiro ANA; Carvalho MA
    J Biol Chem; 2019 Apr; 294(15):5980-5992. PubMed ID: 30765603
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.